– USA, OH – AtriCure, Inc. (NASDAQ: ATRC), a leading innovator in treatments for atrial fibrillation and left atrial appendage management, today announced the appointment of Kris Johnson as Board Chair, succeeding Scott Drake who will not stand for re-election in May 2021.
“Kris’ experience and counsel have been impactful to AtriCure over the past four years, and I’m delighted that she will be serving in this new capacity, particularly as the Company executes on its many upcoming catalysts,” said current Board Chair, Scott Drake.
The Company also announced that Mark Lanning will not stand for re-election at the end of his terms in May 2021.
Mr. Drake, the President, and CEO of ViewRay, Inc., has served on AtriCure’s Board since September of 2013 and has served as Board Chair since May of 2018. Mr. Lanning has served on the Board since February of 2006 and has served on and as the Chair of a variety of Committees during his tenure.
“I want to thank Scott for his service and leadership on the Board, along with his guidance for our business,” said CEO, Michael Carrel. “He has helped me and the rest of the management team in profound ways, and we have been very fortunate to have him on the Board of Directors for the past eight years. I also want to thank Mark for his time on the Board, beginning with some of the very early days at AtriCure. He has been a steady hand in helping the company through a period of significant growth, and his financial acumen and support have been invaluable to our Company.”
About Kris Johnson
Kris Johnson has served on the Board since May of 2017. She is President of Affinity Capital Management, a venture capital firm that invests primarily in seed and early-stage health care companies in the United States.
Also, Ms. Johnson serves on the Boards of Directors for ClearPoint Neuro, Inc., formerly MRI Interventions, ViewRay, Inc. (Nasdaq: VRAY), the University of Minnesota Foundation Investment Advisors, and several private entities.
Ms. Johnson was previously employed for 17 years at Medtronic plc, serving most recently as SVP and Chief Administrative Officer from 1998 to 1999. Her experience at Medtronic also includes service as President of the Vascular Business and President of the Tachyarrhythmia Management Business.
About AtriCure, Inc.
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib-related complications. AtriCure’s Isolator Synergy Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent and long-standing persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide.
For more information: https://www.atricure.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.